Market Outlook

The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix, and Avastin) with or without chemotherapy regimens. The 2017 FDA approvals of Keytruda and Opdivo have expanded treatment options for the minority of patients with MSI-H or dMMR metastatic colorectal cancer. Although the market landscape is evolving at a rapid pace, significant unmet need exists for the development of well-tolerated agents that can improve overall survival and progression-free survival outcomes.

Questions Answered

  • What are the treatment drivers that are most likely to influence a therapy’s uptake for second- and subsequent-line advanced or metastatic colorectal cancer?
  • How do current therapies perform on key treatment drivers and goals for second- and subsequent-line advanced or metastatic colorectal cancer?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across different key clinical attributes and price, when considering hypothetical new treatment options in the second-line setting?

Product Description

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, and the United Kingdom.

Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in March 2018.

Key companies: Roche/Genentech, Eli Lilly/Merck KGaA, Amgen, Taiho Pharmaceutical, Merck & Co., and Bristol-Myers Squibb.

Key drugs: Avastin, Erbitux, Vectibix, Lonsurf, Keytruda, and Opdivo.

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Second- and Subsequent-Line Advanced or Metastatic Colorectal Cancer
      • Key Findings: Unmet Need in Second- and Subsequent-Line Advanced or Metastatic Colorectal Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Second- and Subsequent-Line Advanced or Metastatic Colorectal Cancer Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy with a Substantial Survival Benefit
        • Opportunity: A New Therapy with Improved Progression-Free Survival
        • Opportunity: A Novel Therapy with More Durable Response
        • Opportunity: A Novel Agent with a Better Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Second-Line Advanced or Metastatic Colorectal Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, , is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at University of Science & Technology, Hisar, India.

Related Reports

Colorectal Cancer | Geographic Focus - China | Colorectal Cancer - China In-Depth - China

MARKET OUTLOOK Colorectal cancer, a major public health concern in China, is expected to become the second most common form of cancer there by 2028, behind only lung can...

View Details

Colorectal Cancer | Landscape & Forecast | Disease Landscape & Forecast

Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current treatment for metastatic colorectal cancer is...

View Details

Colorectal Cancer | Epidemiology | Emerging Markets

DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....

View Details

Colorectal Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Market Outlook Chemotherapies and targeted agents continue to dominate the treatment of colorectal cancer, although targeted agents (e.g., Avastin, Erbitux, Vectibix) ar...

View Details